Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

1.

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators.

JAMA Intern Med. 2013 Oct 14;173(18):1682-92.

PMID:
23939297
2.

Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies.

Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W.

Clin Ther. 2012 Apr;34(4):966-78. doi: 10.1016/j.clinthera.2012.02.008. Epub 2012 Mar 7.

PMID:
22401642
3.

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P.

Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Erratum in: Lancet. 2008 Oct 18;372(9647):1384.

PMID:
18757085
4.

Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine.

Malik M, Andreas JO, Hnatkova K, Hoeckendorff J, Cawello W, Middle M, Horstmann R, Braun M.

Clin Pharmacol Ther. 2008 Nov;84(5):595-603. doi: 10.1038/clpt.2008.143. Epub 2008 Jul 23.

PMID:
18650802
5.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.

N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.

6.
7.

Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes.

Rayman G, Profozic V, Middle M.

Diabetes Res Clin Pract. 2007 May;76(2):304-12. Epub 2006 Nov 20.

PMID:
17113676
8.

Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma.

Buhl R, Vinkler I, Magyar P, Györi Z, Rybacki C, Middle MV, Escher A, Engelstätter R.

Pulm Pharmacol Ther. 2006;19(6):404-12. Epub 2005 Nov 28.

PMID:
16310388
9.

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.

Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M.

J Clin Psychopharmacol. 2004 Feb;24(1):62-9.

PMID:
14709949
10.

Bronchodilating effects of salbutamol from a novel inhaler Airmax.

Middle MV, Terblanché J, Perrin VL, Hertog MG.

Respir Med. 2002 Jul;96(7):493-8.

PMID:
12194632
12.

Comparison of the efficacy and tolerability of a paracetamol/codeine fixed-dose combination with tramadol in patients with refractory chronic back pain.

Müller FO, Odendaal CL, Müller FR, Raubenheimer J, Middle MV, Kummer M.

Arzneimittelforschung. 1998 Jun;48(6):675-9.

PMID:
9689426
13.

An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure.

Müller FO, Middle MV, Schall R, Terblanché J, Hundt HK, Groenewoud G.

Br J Clin Pharmacol. 1997 Oct;44(4):393-8.

14.

Bioavailability of two selegiline hydrochloride tablet products.

Müller FO, Schall R, Hundt HK, Joubert A, Middle MV, Muir AR, Duursema L, Groenewoud G, Swart KJ.

Arzneimittelforschung. 1996 Nov;46(11):1037-40.

PMID:
8955861
15.

The efficacy of two bupivacaine hydrochloride injection products.

Müller FO, Claasen JP, Schall R, Mogilnicka EM, Vos DJ, Groenewoud G, Middle MV, Stulting AA.

S Afr Med J. 1996 Jun;86(6):667-9.

PMID:
8764423
16.

No influence of pantoprazole on the pharmacokinetics of phenytoin.

Middle MV, Müller FO, Schall R, Groenewoud G, Hundt HK, Huber R, Bliesath H, Steinijans VW.

Int J Clin Pharmacol Ther. 1996 May;34(1 Suppl):S72-5.

PMID:
8793606
17.

Relative bioavailability of four clomipramine hydrochloride tablet products.

Müller FO, Schall R, Mogilnicka EM, Groenewoud G, Hundt HK, Luus HG, Middle MV, Swart KJ, De Vaal AC.

Biopharm Drug Dispos. 1996 Jan;17(1):81-90.

PMID:
8991493
18.

Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.

Schall R, Müller FO, Hundt HK, Duursema L, Groenewoud G, Middle MV.

Arzneimittelforschung. 1996 Jan;46(1):41-6.

PMID:
8821516
19.

Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.

Schall R, Müller FO, Duursema L, Groenewoud G, Hundt HK, Middle MV, Mogilnicka EM, Swart KJ.

Arzneimittelforschung. 1995 Nov;45(11):1236-9.

PMID:
8929247
20.

Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin.

Duursema L, Müller FO, Schall R, Middle MV, Hundt HK, Groenewoud G, Steinijans VW, Bliesath H.

Br J Clin Pharmacol. 1995 Jun;39(6):700-3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk